Vitrolife Group (VITR) Pre-silent call presentation summary

Group and organisational update

• Restructuring program to rationalise the portfolio and exit low profit markets will be finalised by end of Q3, aiming to improve profitability.

• Share repurchase programme is progressing well and is nearly halfway complete, with further details to be shared in the Q3 report.

• CEO recruitment process is ongoing; Bronwyn Brophy will remain in place for up to 12 months to ensure continuity.

Leadership and management changes

• Erin Schardt appointed SVP and General Manager, Americas, now overseeing both North and South America.

• Schardt joins the Executive Management Team, bringing extensive medtech and genetics experience and deep market knowledge.

• Under Schardt's leadership, North America has seen profitable growth, high-performing teams, and stronger customer partnerships.

Strategic and operational outlook

• Focus remains on strategic continuity and operational stability during the CEO transition.

• Management highlights ongoing macro-economic, operational, and financial risks as described in the annual report.